Summit Therapeutics (SMMT) Sheds 10.4%, This Analyst is Pessimistic

Summit Therapeutics Inc. (NASDAQ:SMMT) is one of the 10 Stocks Entering June in the Wrong Direction.

Summit Therapeutics soared by 10.43 percent on Monday to end at $15.71 apiece, after an investment firm reiterated a pessimistic coverage for its stock.

In a market note during the day, Bernstein reaffirmed its underperform rating for Summit Therapeutics Inc. (NASDAQ:SMMT) alongside a $7.70 price target, marking a 51 percent discount from its latest closing price.

Photo by Tima Miroshnichenko on Pexels

The investment firm said that the coverage reflected expectations of a non-statistically significant overall survival trend for the biopharmaceutical company’s Harmoni-6 trial. It was earlier suggested that investors dispose of positions or initiate short positions where necessary.

In other news, Summit Therapeutics Inc. (NASDAQ:SMMT) over the weekend announced positive overall survival results from the Phase 3 trial to test the efficacy of Ivonescimab in China. The trial was sponsored by its partner, Akeso Inc.

In the study, patients who received Ivonescimab combined with chemotherapy lived significantly longer than those who received tislelizumab plus chemotherapy.

The study also showed that the death risk was slashed by 34 percent compared with tislelizumab, and that the overall survival was seen across different patient groups, including those with high and low PD-L1 expression.

Two years after, Summit Therapeutics Inc. (NASDAQ:SMMT) said that patients treated with ivonescimab were still alive, versus the 48.6 percent in patients treated with tislelizumab.

While we acknowledge the risk and potential of SMMT as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than SMMT and that has 10,000% upside potential, check out our report about the cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.

1281292 - 11759070 - 1